USPTO Patent Application for Cancer Prodrugs
Summary
The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.
What changed
This document is a USPTO patent application (US20260085069A1) for new prodrug compounds that are inhibitors of Casein Kinase 2 alpha (CK2α). These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, inflammation, diabetes, and neurodegenerative disorders. The application specifies chemical structures of Formula II and their use in pharmaceutical compositions.
This is a patent application, not a regulatory rule or guidance. It does not impose new compliance obligations on regulated entities. However, it represents a potential future development in cancer therapeutics, which may be of interest to pharmaceutical companies and researchers in the field. No immediate actions or deadlines are associated with this publication for compliance officers.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PRODRUGS
Application US20260085069A1 Kind: A1 Mar 26, 2026
Inventors
PAUL GLOSSOP
Abstract
Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
CPC Classifications
C07D 471/04 A61K 31/4375
Filing Date
2023-09-08
Application No.
19109796
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.